Klein Lawrence Otto

Chief Executive Officer, DirectorOruka Therapeutics, Inc. (ORKA) · full profile →Form 4 · filed Sep 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$6.9M
Net Open-Market Flow
-$6.9M
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 1, 2026Option exercise(M)75K$7.80$585K1.0M
Sep 1, 2026Sell(S)7K$90.79$600K994K
Sep 1, 2026Sell(S)64K$91.90$5.8M930K
Sep 1, 2026Sell(S)5K$92.44$444K926K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 1, 2026Option exercise(M)75K$01.6M

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000907654-26-000087) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.